Go to Livimmune r/Livimmune • 2d ago BuildGoodThings lets take a peek
On April 30 in a webcast, the CEO of CytoDyn, Dr. Jay Lalezari said "And that has been the great pleasure of being the CEO of CytoDyn lately, as I no longer have to spend my time trying to convince people of anything. I just need to show them our data and that seems to do the trick."
Although we don't have the up-to-the-minute data that Dr. Lalezari has, we do have a bunch. I think it's interesting to reflect on the data he may know, as well as the conversations he's been having, that led to his quote above. In addition to reflecting, it seems sensible IMO to take a peek at what information is out there for investors. CytoDyn has been putting out a lot of information since 2024. IMO the significance of the data as well as the pace of people understanding the potential reach of leronlimab has been increasing. If you are new and want an idea about where to start learning, the company website is https://www.cytodyn.com/
This post has sections for
trials data
papers
abstracts
posters
speaking presentations at science conferences (added May 28, 2026)
interviews
webcasts
This post is not investment advice and it is not medical advice. The post is best viewed on a large screen, but if you view on a phone, you may be able to swipe right or left on the tables to see 3 columns including many links. trial data results at clinicaltrialsgov
I believe it is significant that results from trials have been posted at clinicaltrialsgov and that the results data has met compliance review thresholds in order to have been posted. Date Indication Links April 11, 2024 Inflammation: Covid-19: PASC (a.k.a. Post Covid, or Longhaulers) clinicaltrialsgov (NCT04678830 or CD15), Phase 2, results posted August 27, 2025 Inflammation: Covid-19: Severe & Critical clinicaltrialsgov (NCT04347239 or CD12), Phase 2-3, results posted September 9, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) clinicaltrialsgov (NCT03838367 or CD07), Phase 2b-3, results posted September 16, 2025 HIV: Maintenance therapy clinicaltrialsgov (NCT03902522 or CD02 open label), Phase 2b-3, results posted October 7, 2025 HIV: Maintenance therapy clinicaltrialsgov (NCT02355184) or CD01 extension, Phase 2b, results posted October 30, 2025 HIV: Maintenance therapy clinicaltrialsgov (NCT05271370) or CD03 extension, Phase 2b-3, results posted November 12, 2025 HIV: Maintenance therapy clinicaltrialsgov (NCT02990858 or CD02 extension), Phase 2-3, results posted January 23, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) clinicaltrialsgov (NCT04504942 or CD09 basket), Phase 2, results January 23, 2026 Cancer: Colorectal clinicaltrialsgov (NCT04504942 or CD09 basket), Phase 2, results March 4, 2026 HIV: Maintenance therapy clinicaltrialsgov (NCT02859961 or CD03), Phase 2-3, results posted papers
covering a range of different research Date Indication Links May 19, 2024 Inflammation: Covid-19: PASC (a.k.a. Post Covid, or Longhaulers) paper (publication) in Journal of Infection, phase 2 (Gaylis) September 26, 2024 HIV: Mothers to newborns (leronlimab PLS) paper in mAbs, preclinical (Zikos) September 30, 2024 Inflammation: Covid-19: Mild-Moderate paper in Clinical Therapeutics, phase 2 (Seethamraju ) February 20, 2025 HIV: Maintenance therapy paper in JAIDS, phase 2b/3 (Gathe) June 13, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) paper (update) in International Journal of Molecular Science, reference to phase 2 (Zhang & Harish) October 14, 2025 Inflammation: MASH & Fibrosis paper in Liver International Communications, phase 2 (Palmer) November 6, 2025 Cancer: Colorectal paper preprint, preclinical (Lindner) April 29, 2026 HIV: cure, Gene therapy, AAV viral vector paper in Science Translational Medicine, preclinical (Wu & Webb) May 1, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) paper in Current Problems in Cancer: Case Reports, phase 2 (Dolezal) May 21, 2026 Inflammation: Fibrosis paper in Journal of Liver, preclinical (Palmer) abstracts Date Indication Links July 23, 2024 (Long-acting) abstract at AIDS 2024 (Munich: Wu), preclinical July 23, 2024 HIV: cure, Gene therapy, AAV viral vector abstract at AIDS 2024 (Munich: Webb), preclinical October 9, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP abstract at HIV4P 2024 (Lima: Sacha), preclinical October 23, 2024 HIV: cure, Gene therapy, AAV viral vector abstract at NHP-AIDS 2024 (New Orleans: Sacha), preclinical October 23, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP abstract at NHP-AIDS 2024 (New Orleans: Sacha), preclinical May 6, 2025 HIV: Mothers to newborns (leronlimab PLS) abstract at Immunology 2025 (Honolulu: Magnani), preclinical May 14, 2025 (Long-acting: RNA Structural Switch for mRNA and Gene Therapies) abstract at ASGCT (New Orleans: Ogurlu) oral, preclinical May 15, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract at ESMO Breast Cancer 2025 (Munich: Pestell), phase 2 July 4, 2025 Cancer: Colorectal abstract at ESMO GI 2025 (Barcelona: Weinberg), phase 2 September 24, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract at AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity (Montreal: Pestell), phase 2 September 24, 2025 Cancer: Colorectal abstract at AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity (Montreal: Pestell) November 24, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract at AACR San Antonio Breast Cancer Symposium, 2025, Day 4, poster session 5 (San Antonio: Dolezal), phase 2 February 18, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract at AACR IO 2026 (Los Angeles: Pestell), phase 2 March 17, 2026 Cancer: Colorectal abstract (regular) AACR Annual Meeting 2026 (San Diego: Kasi) March 17, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract title & text (regular) AACR Annual Meeting 2026 (San Deigo: Pestell) March 23, 2026 Cancer: Glioblastoma abstract at AACR Brain Cancer Conference, (Philadelphia: Li), preclinical April 3, 2026 Cancer: Colorectal abstract published (regular) AACR Annual Meeting 2026 in Cancer Research (San Diego: Kasi) April 3, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstracts published (regular) AACR Annual Meeting 2026 in Cancer Research (San Diego: Pestell) April 21, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) Abstract title at ASCO26 Annual Meeting (Chicago: Tripathy), phase 2 April 21, 2026 Cancer: Colorectal Abstract title at ASCO26 Annual Meeting (Chicago: Kasi), phase 2 May 12, 2026 Cancer: Colorectal abstracts & skeleton submissions for Late-Breaking abstracts due for ESMO 2026 Congress Madrid (October 23-27) May 21, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) abstract at ASCO26 Annual Meeting released (Chicago: Tripathy), phase 2 May 21, 2026 Cancer: Colorectal abstract at ASCO26 Annual Meeting released (Chicago: Kasi), phase 2 posters
showing state of the art understandings Date Indication Links July 23, 2024 (Long-acting) poster at AIDS 2024 (Munich: Wu), preclinical July 23, 2024 HIV: cure, Gene therapy, AAV viral vector poster at AIDS 2024 (Munich: Webb), preclinical May 15, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) poster at ESMO Breast Cancer 2025 (Munich, Pestell), phase 2 July 4, 2025 Cancer: Colorectal poster at ESMO GI 2025 (Barcelona: Weinberg) phase 2, line about current P2 CRC July 4, 2025 Cancer: Colorectal poster at ESMO GI 2025 (Barcelona: Weinberg), phase 2 September 26, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) poster at AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, (Montreal: Pestell), phase 2 September 26, 2025 Cancer: Colorectal poster at AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, (Montreal: Pestell), phase 2 December 12, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) poster at AACR SABC Symposium 2025 (San Antonio: Dolezal), phase 2 February 18, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) poster at AACR IO 2026 (Los Angeles: Pestell), phase 2 April 19, 2026 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) poster published AACR Annual Meeting 2026 (San Diego: Pestell), phase 2 April 21, 2026 Cancer: Colorectal poster published AACR Annual Meeting 2026 (San Diego: Kasi), phase 2 Speaking presentations at scientific conferences Date Indication Links October 9, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP presentation: HIV4P 2024 (Lima: Sacha) see rapporteur summary tab October 9, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP presentation: HIV4P 2024 (Lima: Sacha) slideshow (HTML), preclinical October 9, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP presentation: HIV4P 2024 (Lima: Sacha) slideshow (PowerPoint), preclinical October 9, 2024 HIV: cure, Triple therapy (ART+bNAbs+Leronlimab) also PreP presentation: HIV4P 2024 (Lima: Sacha) video & slideshow, preclinical September 27, 2025 Cancer: Breast Cancer (Triple Negative Breast Cancer, TNBC) presentation: AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, (Montreal), Richard Pestell September 27, 2025 Cancer: Colorectal presentation: AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, (Montreal), Richard Pestell October 2, 2025 (Long-acting) presentation: 42nd Annual Symposium on Nonhuman Primate Models for AIDS (Madison: Wu), preclinical October 2, 2025 HIV: cure, Gene therapy, AAV viral vector presentation: 42nd Annual Symposium on Nonhuman Primate Models for AIDS (Madison: Sacha), preclinical October 2, 2025 HIV: cure, Gene therapy, AAV viral vector presentation: 42nd Annual Symposium on Nonhuman Primate Models for AIDS (Madison: Webb), preclinical May 5, 2026 HIV: cure, Gene therapy, AAV viral vector presentation at OHSU, preclinical interviews with CEO
putting the science into words for more to understand Date Indication Links August 20, 2025 numerous diseases interview: CEO Dr. Jay Lalezari with Ira Pastor October 14, 2025 numerous diseases interview: CEO Dr. Jay Lalezari with Chris Leidli November 14, 2025 numerous diseases interview: CEO Dr. Jay Lalezari with Karen Jagoda February 6, 2026 numerous diseases interview: CEO Dr. Jay Lalezari with Citeline webcasts including CEO
laying out the scope of what is happening Date Indication Links September 10, 2025 numerous diseases webcast unofficial transcript April 30, 2026 numerous diseases Investor webcast
00:24:31 Robert Hoffman, CFO, CytoDyn "I will, I guess, announce that we do have a commitment from a checkpoint inhibitor company to provide us with their drug. That is really positive. More on that as we move forward later in the year."
00:12:16 Robert Hoffman, CFO, CytoDyn "We have a very well known prominent institution looking at pancreatic cancer for us, that we hope to announce later this year"
Market Data 
Markets 
